| # | Drug | Count |
|---|---|---|
| 0 | CONJUGATED ESTROGENS | 105 |
| 1 | ESTROGENS, CONJUGATED | 105 |
| 2 | MEDROXYPROGESTERONE ACETATE | 105 |
| 3 | CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE | 103 |
| 4 | TRASTUZUMAB | 38 |
| 5 | ALENDRONATE SODIUM | 34 |
| 6 | ERGOCALCIFEROL | 34 |
| 7 | PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF | 34 |
| 8 | ETANERCEPT | 33 |
| 9 | PERTUZUMAB | 33 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | BUTALBITAL, ASPIRIN, AND CAFFEINE | 2 | 0.0116 |
| 1 | PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF | 34 | 0.0070 |
| 2 | NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE | 1 | 0.0049 |
| 3 | CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE | 103 | 0.0044 |
| 4 | BORIC ACID | 1 | 0.0028 |
| 5 | ESTROGEN | 8 | 0.0027 |
| 6 | ESTRADIOL AND NORETHINDRONE ACETATE | 1 | 0.0026 |
| 7 | INFLIXIMAB-DYYB | 7 | 0.0020 |
| 8 | ONTRUZANT | 1 | 0.0019 |
| 9 | CONJUGATED ESTROGENS | 105 | 0.0018 |
| # | Drug class | Count |
|---|---|---|
| 0 | Estrogen [EPC] | 122 |
| 1 | HER2/neu Receptor Antagonist [EPC] | 79 |
| 2 | Tumor Necrosis Factor Blocker [EPC] | 70 |
| 3 | Nonsteroidal Anti-inflammatory Drug [EPC] | 54 |
| 4 | Kinase Inhibitor [EPC] | 52 |
| 5 | Aromatase Inhibitor [EPC] | 40 |
| 6 | Benzodiazepine [EPC] | 36 |
| 7 | Corticosteroid [EPC] | 36 |
| 8 | Endoglycosidase [EPC] | 34 |
| 9 | Provitamin D2 Compound [EPC] | 34 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Interleukin-5 Antagonist [EPC] | 13 | 0.0189 |
| 1 | Endoglycosidase [EPC] | 34 | 0.0183 |
| 2 | Guanylate Cyclase-C Agonist [EPC] | 3 | 0.0014 |
| 3 | Provitamin D2 Compound [EPC] | 34 | 0.0011 |
| 4 | HER2/neu Receptor Antagonist [EPC] | 79 | 0.0011 |
| 5 | Estrogen [EPC] | 122 | 0.0007 |
| 6 | Calcitonin Gene-related Peptide Receptor Antagonist [EPC] | 4 | 0.0006 |
| 7 | Dopamine and Norepinephrine Reuptake Inhibitor [EPC] | 2 | 0.0005 |
| 8 | Sulfonamide Antibacterial [EPC] | 2 | 0.0005 |
| 9 | Aromatase Inhibitor [EPC] | 40 | 0.0004 |